These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 26350813

  • 21. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.
    Rashid S, Tavori H, Brown PE, Linton MF, He J, Giunzioni I, Fazio S.
    Circulation; 2014 Jul 29; 130(5):431-41. PubMed ID: 25070550
    [Abstract] [Full Text] [Related]

  • 22. Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment.
    Kwakernaak AJ, Lambert G, Slagman MC, Waanders F, Laverman GD, Petrides F, Dikkeschei BD, Navis G, Dullaart RP.
    Atherosclerosis; 2013 Feb 29; 226(2):459-65. PubMed ID: 23261172
    [Abstract] [Full Text] [Related]

  • 23. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
    Nekaies Y, Baudin B, Kelbousi S, Sakly M, Attia N.
    J Diabetes Complications; 2015 Feb 29; 29(8):1165-70. PubMed ID: 26412029
    [Abstract] [Full Text] [Related]

  • 24. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents.
    Baass A, Dubuc G, Tremblay M, Delvin EE, O'Loughlin J, Levy E, Davignon J, Lambert M.
    Clin Chem; 2009 Sep 29; 55(9):1637-45. PubMed ID: 19628659
    [Abstract] [Full Text] [Related]

  • 25. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A, Watts GF.
    Clin Ther; 2013 Aug 29; 35(8):1082-98. PubMed ID: 23932550
    [Abstract] [Full Text] [Related]

  • 26. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
    Brouwers MC, Konrad RJ, van Himbergen TM, Isaacs A, Otokozawa S, Troutt JS, Schaefer EJ, van Greevenbroek MM, Stalenhoef AF, de Graaf J.
    Nutr Metab Cardiovasc Dis; 2013 Nov 29; 23(11):1115-21. PubMed ID: 23333725
    [Abstract] [Full Text] [Related]

  • 27. Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention.
    Zhu YM, Anderson TJ, Sikdar K, Fung M, McQueen MJ, Lonn EM, Verma S.
    Arterioscler Thromb Vasc Biol; 2015 Oct 29; 35(10):2254-9. PubMed ID: 26293463
    [Abstract] [Full Text] [Related]

  • 28. The effect of insulin on circulating PCSK9 in postmenopausal obese women.
    Awan Z, Dubuc G, Faraj M, Dufour R, Seidah NG, Davignon J, Rabasa-Lhoret R, Baass A.
    Clin Biochem; 2014 Aug 29; 47(12):1033-9. PubMed ID: 24721682
    [Abstract] [Full Text] [Related]

  • 29. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.
    Chan DC, Watts GF, Somaratne R, Wasserman SM, Scott R, Barrett PHR.
    Arterioscler Thromb Vasc Biol; 2018 Jul 29; 38(7):1644-1655. PubMed ID: 29880491
    [Abstract] [Full Text] [Related]

  • 30. The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis.
    Bonnefond A, Yengo L, Le May C, Fumeron F, Marre M, Balkau B, Charpentier G, Franc S, Froguel P, Cariou B, DESIR study group.
    Diabetologia; 2015 Sep 29; 58(9):2051-5. PubMed ID: 26049403
    [Abstract] [Full Text] [Related]

  • 31. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.
    Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R, Karmally W, Nandakumar R, Fontanez N, Obunike J, Marcovina SM, Lichtenstein AH, Matthan NR, Matta J, Maroccia M, Becue F, Poitiers F, Swanson B, Cowan L, Sasiela WJ, Surks HK, Ginsberg HN.
    Circulation; 2017 Jan 24; 135(4):352-362. PubMed ID: 27986651
    [Abstract] [Full Text] [Related]

  • 32. WAT apoC-I secretion: role in delayed chylomicron clearance in vivo and ex vivo in WAT in obese subjects.
    Cyr Y, Wassef H, Bissonnette S, Lamantia V, Davignon J, Faraj M.
    J Lipid Res; 2016 Jun 24; 57(6):1074-85. PubMed ID: 27040450
    [Abstract] [Full Text] [Related]

  • 33. Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease.
    Zhang Y, Xu RX, Li S, Zhu CG, Guo YL, Sun J, Li JJ.
    Nutr Metab Cardiovasc Dis; 2015 Apr 24; 25(4):426-33. PubMed ID: 25770756
    [Abstract] [Full Text] [Related]

  • 34. Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins.
    Kwakernaak AJ, Lambert G, Dullaart RP.
    Clin Biochem; 2014 May 24; 47(7-8):679-82. PubMed ID: 24680982
    [Abstract] [Full Text] [Related]

  • 35. Plasma proprotein convertase subtilisin kexin type 9 is a heritable trait of familial combined hyperlipidaemia.
    Brouwers MC, van Greevenbroek MM, Troutt JS, Bonner Freeman A, Lu A, Schaper NC, Konrad RJ, Stehouwer CD.
    Clin Sci (Lond); 2011 Nov 24; 121(9):397-403. PubMed ID: 21539517
    [Abstract] [Full Text] [Related]

  • 36. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.
    Lambert G, Jarnoux AL, Pineau T, Pape O, Chetiveaux M, Laboisse C, Krempf M, Costet P.
    Endocrinology; 2006 Oct 24; 147(10):4985-95. PubMed ID: 16794006
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J, Bogsrud MP, Tveten K, Strøm TB, Holven K, Berge KE, Leren TP.
    Transl Res; 2012 Aug 24; 160(2):125-30. PubMed ID: 22683370
    [Abstract] [Full Text] [Related]

  • 39. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
    Jin K, Park BS, Kim YW, Vaziri ND.
    Am J Kidney Dis; 2014 Apr 24; 63(4):584-9. PubMed ID: 24315769
    [Abstract] [Full Text] [Related]

  • 40. White Adipose Tissue Surface Expression of LDLR and CD36 is Associated with Risk Factors for Type 2 Diabetes in Adults with Obesity.
    Cyr Y, Bissonnette S, Lamantia V, Wassef H, Loizon E, Ngo Sock ET, Vidal H, Mayer G, Chrétien M, Faraj M.
    Obesity (Silver Spring); 2020 Dec 24; 28(12):2357-2367. PubMed ID: 33043593
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.